ArticleChild's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery2026
Outcomes in children receiving single-fraction Gamma Knife radiosurgery for arteriovenous malformation.
Article in Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionStereotactic radiosurgery (SRS) is used for arteriovenous malformations (AVM), but the risk for secondary malignancy (SM), radiation necrosis (RN), obliteration rates (ObR), and late neurologic toxicities in pediatric patients is not well defined. To address this, we reviewed our two-decade-long institutional experience treating pediatric AVMs with SRS.
methodsRetrospective review of patients receiving single-fraction SRS for AVM between 1/2006 and 12/2023. ObR and RN were determined on neuroimaging, and toxicities by clinical evaluation. Overall follow-up was 56 months (range 6-193); 59 patients had follow-up > 36 months (median 85 months).
resultsEighty-nine patients/101 AVMs were treated at average age of 12.9 years (range 2.36-20.1). Median follow-up was 56 months (range 6-193); 59 patients (66.3%) had > 36 months of follow-up (median 85 months). Average AVM volume was 2.85 cm
conclusionSingle-fraction SRS for AVMs is effective, with a high obliteration rate and low radionecrosis rates. No secondary malignancies, hemorrhages, or deaths occurred.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.